TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02179424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workshop
Description: Intensive psychological intervention included motivation of quitting enhancement, stress management and smoking triggers, craving and relapse are used to provide smoking cessation intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face counseling
Description: Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone counseling
Description: Use motivational interview strategies through phone counseling to provide smoking cessation intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone counseling
Description: Use motivational interview strategies through phone counseling to provide smoking cessation intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health talk
Description: Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booklet
Description: A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booklet
Description: A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booklet
Description: A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS
Description: Fifteen SMS were sent to subjects included welcome messages, risk of smoking, correction of myths about smoking or quitting, quitting tips, benefits of quitting, encouragement of quitting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS
Description: Fifteen SMS were sent to subjects included welcome messages, risk of smoking, correction of myths about smoking or quitting, quitting tips, benefits of quitting, encouragement of quitting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS
Description: Fifteen SMS were sent to subjects included welcome messages, risk of smoking, correction of myths about smoking or quitting, quitting tips, benefits of quitting, encouragement of quitting
Study: NCT03926741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSNO
Description: patient will use a nebulizer to inhale (breathe in) a solution of GSNO followed by repeated measurements of airway function (breathing tests)
Study: NCT03729583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: A 12 week high intensity PR programme was delivered to both groups. The active group had additional breathing control interventions and exercises

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: A 12 week high intensity PR programme was delivered to both groups. The active group had additional breathing control interventions and exercises
Study: NCT00883116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study: NCT02662491

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03674073

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen Vaccines
Description: HCC (3cm≤D ≤5 cm, fewer than three tumors) patients were treated with Microwave Ablation and 7 courses of neoantigen-based DC vaccines.The first neoantigen-based DC vaccine injection will take place up to 30 days following the completion of Microwave Ablation. The day of the first vaccine injection will be referred to as Day 1.The schedule of vaccination is Day 1, Day 8, Day 15, Day 22, Day 50, Day78, Day106.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microwave Ablation
Description: ALL the HCC patients will be treated by Microwave Ablation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation
Description: ALL the HCC patients will be treated by Microwave Ablation.
Study: NCT04500002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isonicotinic Acid Hydrazide
Description: total dose 900 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprosrol 800mcg will be given to all patients for induction of abortion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprosrol 800mcg will be given to all patients for induction of abortion
Study: NCT01357538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Posiformin 2 %, bibrocathol
Description: A strip of 5 mm eye ointment applied 3 times per day to the eye lid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: corresponding vehicle, eye ointment applied to the eye lid
Study: NCT03352622

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CASES
Description: Patients with RA with methotrexate therapy and inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; That present problems of effectiveness.
Study: NCT01291810

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNF Kinoid
Description: TNF Kinoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: WFI
Description: WFI
Study: NCT03352622

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROLS
Description: Patients with RA with methotrexate therapy inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; No problems of effectiveness
Study: NCT03592108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSR remote monitoring
Description: The intervention will consist to modify the method used to analyse the data collected by remote monitoring in OSA-patients treated by CPAP (device : AirSense™10 Autoset™, ResMed) in order to alert physicians when Cheynes-Stokes respiration (CSR) occurs during sleep and then to set up emergency pulmonology and cardiology consultations to screen the onset of a significant cardiac event (heart failure, rhythm disorder, diastolic dysfunction).
Study: NCT04008615

Intervention type: OTHER
Intervention: 2 times : 6-minute stepper test with cardiorespiratory parameters and gaz exchange monitoring (with a rest of 20min between each test).
Description: For the 6-minute stepper test, please refer to NCT02842463 and NCT04004689. Gaz exchange analyzer will be calibrate before every test. Data will be recorded breath by breath.~Heart rate will be monitored using a 12-lead electrocardiogram. Transcutaneous oxygen saturation will be assessed using a pulse oxymetry system at the earlobe.
Study: NCT01554553

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior crural repair
Description: All patients receive gastrectomy, however patients randomized to the experimental arm will also receive posterior crural repair to determine if this will reduce GERD post sleeve gastrectomy.
Study: NCT01635946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: oral
Study: NCT02045134

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soluble corn flour not rich in anthocyanins

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-anthocyanin rich corn flour
Description: Soluble corn flour at high content in anthocyanins
Study: NCT02593474

Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone
Description: Outpatient detoxification and induction onto long-acting naltrexone followed by an additional second injection of long-acting naltrexone and and additional third if desired.
Study: NCT04719026

Intervention type: OTHER
Intervention: Full-mouth periodontal examination using computerised Florida probe
Description: It is an observational study to investigate the prevalence of periodontitis in cases and controls.

Intervention type: OTHER
Intervention: Full-mouth periodontal examination using computerised Florida probe
Description: It is an observational study to investigate the prevalence of periodontitis in cases and controls.
Study: NCT03035851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stretch and Strength
Study: NCT00515814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retina implant is surgically placed into subretinal position
Description: Subretinal implant is either in ON or in OFF condition during test periods, such as FrACT, BaLM, grating, orientation \& mobility.
Study: NCT04053270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Description: 16mg subcutaneous implant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Afamelanotide
Description: 16mg subcutaneous implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo subcutaneous implant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous implant
Study: NCT02191891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836845
Description: Human monoclonal antibody. Two dose levels (high or low) depending on the dose cohort explored

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: Irreversible EGFR tyrosine kinase inhibitor. Two dose levels (30 mg, 40 mg) depending on the dose cohort explored or determined dose at part A
Study: NCT03781375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Administered by subcutaneous injection twice a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etanercept
Description: Administered by subcutaneous injection twice a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Etanerceot
Description: Administered by subcutaneous injection twice a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally or subcutaneously once a week at the same dose as prior to study entry

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Administered orally or subcutaneously once a week at the same dose as prior to study entry
Study: NCT01218841

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil lipid emulsion
Description: 0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MCT/LCT
Description: 0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.
Study: NCT03220334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: The experimental group was treated with PRP for artificial gastric ulcer after ESD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The control group was treated with normal saline for artificial gastric ulcer after ESD.
Study: NCT01303510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V
Description: Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2008-2009 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Florida/4/2006-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V
Description: Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2008-2009 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Florida/4/2006-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1
Study: NCT01485887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Description: Treatment phase: 10 months (75-225 mg/day), oral administration Tapering phase: 1-3 weeks (stepwise dose reduction: 150-37.5 mg/day), oral administration
Study: NCT01578941

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diary
Description: Each subject will be asked to keep a careful headache diary (appendix B) , and in that diary she will record onset and cessation of menstrual flow, days of menstrual headache (and migraine headache, specifically) experienced, days of functionally incapacitating headache experienced, any abortive/symptomatic medications taken, any days of work-related absenteeism (\>4 hrs) related to acute MM headache and any unscheduled visits to a medical facility for acute treatment of MM.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diary
Description: Each subject will be asked to keep a careful headache diary (appendix B) , and in that diary she will record onset and cessation of menstrual flow, days of menstrual headache (and migraine headache, specifically) experienced, days of functionally incapacitating headache experienced, any abortive/symptomatic medications taken, any days of work-related absenteeism (\>4 hrs) related to acute MM headache and any unscheduled visits to a medical facility for acute treatment of MM.
Study: NCT04639869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenyramydol HCl 400 mg Film Tablet
Description: Phenyramydol HCL 400 mg Film Tablet contains 400 mg phenyramydol manufactured by Pharmactive Ilac.San ve Tic A.S

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenyramydol HCl 400 mg Film Tablet
Description: Phenyramydol HCL 400 mg Film Tablet contains 400 mg phenyramydol manufactured by Pharmactive Ilac.San ve Tic A.S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenyramydol HCl 400 mg Film Tablet
Description: Phenyramydol HCL 400 mg Film Tablet contains 400 mg phenyramydol manufactured by Pharmactive Ilac.San ve Tic A.S
Study: NCT03542656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amyloid PET
Description: Dynamic PET acquisition for 60 minutes will be acquired after injection of 10 mCi 11C-PiB (39 frames: 8 x 15 seconds, 4 x 60 seconds, 27 x120 seconds).
Study: NCT04639869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenyramydol HCl 400 mg Film Tablet
Description: Phenyramydol HCL 400 mg Film Tablet contains 400 mg phenyramydol manufactured by Pharmactive Ilac.San ve Tic A.S

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabral 400 mg Film Tablet
Description: Cabral 400 mg Film Tablet 400 mg phenyramydol manufactured by Recordati Ilac SAn ve Tic A.S.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabral 400 mg Film Tablet
Description: Cabral 400 mg Film Tablet 400 mg phenyramydol manufactured by Recordati Ilac SAn ve Tic A.S.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabral 400 mg Film Tablet
Description: Cabral 400 mg Film Tablet 400 mg phenyramydol manufactured by Recordati Ilac SAn ve Tic A.S.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabral 400 mg Film Tablet
Description: Cabral 400 mg Film Tablet 400 mg phenyramydol manufactured by Recordati Ilac SAn ve Tic A.S.
Study: NCT03739866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir
Description: Administered subcutaneously in the abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir
Description: Administered subcutaneously in the abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir
Description: Administered subcutaneously in the abdomen
Study: NCT03974503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure, Relaxation, and Rescripting Therapy
Description: ERRT is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in trauma-exposed adults.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep and Nightmare Management
Description: This is a manualized protocol developed to be of similar length but exclude the active components of standard ERRT.
Study: NCT03713580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Adding Venetoclax, a BCL-2 inhibitor, to standard high dose therapy prior to autologous stem cell transplant (ASCT).~Venetoclax is a novel, orally bioavailable, small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor.
Study: NCT05142800

Intervention type: DEVICE
Intervention: Perometer
Description: The perometer uses light sensors to calculate the length and volume of your arms

Intervention type: DEVICE
Intervention: Perometer
Description: The perometer uses light sensors to calculate the length and volume of your arms

Intervention type: DEVICE
Intervention: SOZO device
Description: The machine measures the amount of fluid on the arm(s)

Intervention type: DEVICE
Intervention: SOZO device
Description: The machine measures the amount of fluid on the arm(s)
Study: NCT03655561

Intervention type: OTHER
Intervention: Non interventional research
Description: Participants are receiving the standard of care according to Nigerian Center for Disease Control (NCDC) Standard Operating Procedures for Lassa fever case management. This include the administration of intravenous ribavirin for Lassa confirmed cases as well as critically-ill Lassa suspected cases.

Intervention type: OTHER
Intervention: Non interventional research
Description: Participants are receiving the standard of care according to Nigerian Center for Disease Control (NCDC) Standard Operating Procedures for Lassa fever case management. This include the administration of intravenous ribavirin for Lassa confirmed cases as well as critically-ill Lassa suspected cases.
Study: NCT02227082

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: The whole breast and regional lymph nodes will receive 23 x 2.03 Gy per fraction (total 46.69 Gy) At the macroscopic tumor a added SIB will be given of 23 x 0.63Gy . Total dose: 61.18 Gy
Study: NCT00974415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2
Description: CO2 treatment delivered to randomized flank at each study visit

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham treatment to other flank at each study visit
Study: NCT03992274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced implementation of PrEP
Description: During Enhanced Implementation study sites will receive Implementation Support to plan and introduce PrEP by following the eight stages of the PrEP-adapted SIC. Implementation Support specifically will involve a centralized technical assistance system developed using US-based PrEP experience focused on addressing implementation issues identified through real-time analysis of client, clinic, and implementation data.
Study: NCT03421730

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System
Description: The VR647 Inhalation System consists of the VR647 Inhalation System 1 control unit, a VR647 nebulizer handset, a mouthpiece and VR647 Smart Cards designed specifically for this trial.
Study: NCT03739866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir
Description: Administered subcutaneously in the abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir
Description: Administered subcutaneously in the abdomen
Study: NCT02227082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, 300 and 400 mg BID
Study: NCT00820859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TREA (Treatment Routes for Exploring Agitation)
Description: Individualized non-pharmacological treatment plan for agitation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Control Group
Description: A presentation on the treatment of behavior problems in dementia given to the staff caregivers of the comparison group
Study: NCT00632827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy medication used to treat a number of types of cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navelbine
Description: Navelbine is an chemotherapy medication used to treat a number of types of cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride Liposome Injection
Description: Doxorubicin Hydrochloride Liposome Injection is an anti-cancer chemotherapy drug
Study: NCT03421730

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer
Description: Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) delivered by a conventional jet nebulizer operated to sputtering.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer
Description: Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) delivered by a conventional jet nebulizer operated to sputtering.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer
Description: Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) delivered by a conventional jet nebulizer operated to sputtering.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer
Description: Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) delivered by a conventional jet nebulizer operated to sputtering.